EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of resistance to antibody-drug conjugates in breast cancer

Baris Cerci, Ozge Saatci, Mark Basik, Ozgur Sahin

Drug Resistance Updates · 2026-03 · 85 · 101353

DOI: 10.1016/j.drup.2026.101353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Baris Cerci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Breast Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugate (ADC) is a drug modality where a payload is conjugated to an antibody for its targeted delivery to the cancer cells. In breast cancer, the treatment landscape has changed remarkably in the past decade by the introduction of several effective ADCs in the clinic. However, intrinsic (de novo) or acquired resistance to these treatments is a major obstacle. In this review, we summarize the role of target antigen alterations, cell-intrinsic mechanisms that overcome payload cytotoxicity, and the pro-tumorigenic tumor microenvironment (TME) as the major drivers of resistance to ADCs. Furthermore, we discuss how different mechanisms of ADC resistance are integrated and highlight the most clinically relevant ones. We then provide the current and emerging strategies, such as biomarker-guided drug combinations and novel ADC designs to overcome resistance to ADCs. Finally, we provide future perspectives on the use of preclinical models that better reflect both intratumor heterogeneity and TME, integration of exploratory biomarker analysis through multi-omics of patient biopsies in prospective clinical trials, and development of new ADCs, e.g., bispecific ADCs and identification of novel antigens and/or payloads, to overcome ADC resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesBreast NeoplasmsDrug Resistance, NeoplasmAntineoplastic AgentsHumansFemaleTumor MicroenvironmentAnimalsBiomarkers, Tumor

Stichwörter der Autor:innen

Antibody-drug conjugate (ADC)Breast cancerBystander effectMechanisms of resistancePayloadTarget antigenTumor immune microenvironment

Substanzen

ImmunoconjugatesBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
  • Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada; Department of Surgery, McGill University, Montreal, QC, Canada.
  • Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: sahinozgur@gmail.com.

Förderung

  • NCI NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Cerci, B., Saatci, O., Basik, M., & Sahin, O. (2026). Mechanisms of resistance to antibody-drug conjugates in breast cancer. Drug Resistance Updates, 85, 101353. https://doi.org/10.1016/j.drup.2026.101353

Vancouver

Cerci B, Saatci O, Basik M, Sahin O. Mechanisms of resistance to antibody-drug conjugates in breast cancer. Drug Resistance Updates. 2026;85:101353. doi:10.1016/j.drup.2026.101353

BibTeX
@article{Cerci2026,
  author = {Cerci, Baris and Saatci, Ozge and Basik, Mark and Sahin, Ozgur},
  title = {Mechanisms of resistance to antibody-drug conjugates in breast cancer},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {85},
  pages = {101353},
  doi = {10.1016/j.drup.2026.101353}
}
Kostenlos starten →